Positive results from Puricore's Vashe Wound Therapy efficacy trial

PuriCore (LSE:PURI), the life sciences company focused on developing and commercializing proprietary solutions that safely, effectively, and naturally kill infectious pathogens, today announced results of a randomized clinical trial showing the potential effectiveness of its Vashe Wound Therapy in the post-operative care of split-thickness skin grafts for burn injuries. Vashe Wound Therapy is a medical device that produces a biocompatible solution to enhance the clinical management of acute and chronic wounds and has been used successfully and without report of adverse events in more than 100,000 wound treatments. It is a safe, effective, and economical alternative to commonly used wound irrigating solutions that inhibit wound healing.

The clinical trial was conducted by Kevin Foster, MD, MBA, FACS, Co-Director of the Arizona Burn Center at the Maricopa Medical Center in Phoenix, Arizona. Results showed that Vashe Wound Therapy is as effective as the control, 5% Sulfamylon® solution (mafenide acetate, USP), a synthetic antimicrobial agent, in the post-operative care of grafts for burns and potentially provides greater pain control. The average graft take for Vashe Wound Therapy and 5% Sulfamylon was 97.4% and 96%, respectively. Infection rates during the trial were equivalent, and none were attributable to the therapy. Further, the trial showed that Vashe Wound Therapy demonstrated greater than a 50% cost savings compared with 5% Sulfamylon. Dr. Foster presented results of this trial at the Southern Regional Burn Conference on November 7, 2009, in Shreveport, LA.

"Vashe Wound Therapy is an exciting new alternative technology that demonstrates clinical efficacy for post operative skin graft irrigation while offering significant overall cost savings,” said Dr. Foster. “This trial also suggests that Vashe has further potential for pain improvement opportunities."

“These clinical results are further evidence that Vashe Wound Therapy is highly effective for wound care, offering an additional boost to the body’s own defense and without any cytotoxic effects that can slow the rate of wound healing,” said PuriCore CEO Greg Bosch. “With the increasing attention to cost-containment in healthcare, Vashe Wound Therapy offers a new cost-effective alternative to traditional wound irrigants.”

Source:

 PuriCore

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
You might also like... ×
Study shows efficacy of a heterologous vaccine regimen to induce mucosal protection against COVID-19